

2025 WellPower Preferred Drug List



The following Preferred Drug List is an abbreviated version of commonly prescribed medications. This list is intended as a guide only. Prescribers should still use generics when possible.

Member-specific benefit plan designs may not cover certain categories or medications, regardless of their appearance in this document.

This Preferred Drug List is subject to change at any time without written notice.

Prior Authorization. There may be times when certain prescription drugs require prior authorization before they can be dispensed. If your medication is rejected at the pharmacy, please contact Customer Service for assistance.

STEP Therapy. There may be times when you are required to try one or more prerequisite drugs prior to the use of another more costly drug, unless you first obtain prior authorization. Usually, your pharmacist will coordinate this with your physician. If you need assistance with this, however, please call Customer Service.



Preferred Drug List (PDL)

EFFECTIVE DATE JANUARY 1, 2025. THIS LIST IS SUBJECT TO CHANGE

PDL DRUG CATEGORY	GENERIC	PREFERRED BRAND	NON-PREFERRED BRAND	EXCLUDED
ALLERGY				
NASAL CORTICOSTEROIDS	azelastine/fluticasone OTC budesonide flunisolide fluticasone mometasone OTC triamcinolone	Qnasl Xhance		Beconase AQ Dymista Omnaris Ticanase Zetonna
OPHTHALMIC ANTIHISTAMINES	azelastine epinastine olopatadine	Alomide		Bepreve Emadine Lastacaft Pazeo
BEHAVIORAL HEALTH				
ADHD AGENTS	amphetamine sulfate dexamethylphenidate dextroamphetamine/ amphetamine dextroamphetamine/ amphetamine ER dextroamphetamine ER dextroamphetamine methylphenidate methylphenidate ER lisdexamfetamine dimesylate	Azstarys Jornay PM	Dyanavel XR Evekeo ODT Qelbree Quillichew Quillivant Zenzedi	Adhansia XR Adzenys ER Adzenys XR-ODT amphetamine ER Aptensio XR Cotempla XR-ODT methylphenidate ER (72mg) Relexii Xelstrym
ANTIPSYCHOTICS	aripiprazole aripiprazole ODT/oral sln asenapine clozapine clozapine ODT lurasidone olanzapine paliperidone quetiapine IR/XR risperidone risperidone ER ziprasidone	Abilify Asimtufii Abilify Maintenance Aristada Invega Hafyera/Sustenna/Trinza Perseris Rexulti Rykindo Uzedy Vraylar	Caplyta Fanapt Fazaclo Secuado Versacloz Zyprexa Relprevv	Abilify Mycite Lybalvi quetiapine (150mg)
CARDIOVASCULAR				
LIPID-LOWERING AGENTS	atorvastatin ezetimibe fluvastatin IR/ER lovastatin IR/ER Livalo pravastatin rosuvastatin simvastatin tablet simvastatin/ezetimibe		Altoprev Atorvaliq Ezallor Sprinkle Flolipid Zypitamag	pitavastatin calcium Roszet
ANTICOAGULANTS	dabigatran	Eliquis Xarelto	Bevyxxa Pradaxa	Savaysa
PCSK9 INHIBITORS		Repatha		Praluent
ACL INHIBITORS		Nexletol Nexlizet		
DERMATOLOGY				
ACTINIC KERATOSIS AGENTS	diclofenac 3% fluorouracil 0.5% fluorouracil 5%	Tolak Klisyri	Fluoroplex	Carac 0.5% Picato Zyclara



Preferred Drug List (PDL)

EFFECTIVE DATE JANUARY 1, 2025. THIS LIST IS SUBJECT TO CHANGE

PDL DRUG CATEGORY	GENERIC	PREFERRED BRAND	NON-PREFERRED BRAND	EXCLUDED
DIABETES				
DPP-4 INHIBITORS		Januvia Janumet Janumet XR		alogliptin alogliptin/metformin alogliptin/pioglitazone Jentadueto Jentadueto XR Kazano Kombiglyze XR Nesina (brand and authorized generic) Onglyza Oseni Tradjenta Zituvio (brand and authorized generic)
SGLT-2 INHIBITORS		Farxiga Jardiance Synjardy Synjardy XR Xigduo XR		Brenzavvy dapagliflozin propanediol dapaglifloz propaned/metformin Inpefa Invokana Invokamet Invokamet XR Segluromet Steglatro
DPP-4 INHIBITOR AND SGLT-2 INHIBITOR COMBINATIONS		Glyxambi Trijardy XR		Qtern Steglujan
GLP-1 AGONISTS		Bydureon Bydureon BCise Byetta Mounjaro Ozempic Rybelsus Trulicity	Liraglutide	Adlyxin
INSULINS, RAPID-ACTING	insulin lispro	Humalog (U-200) Lyumjev	Afrezza	Admelog Apidra Fiasp insulin aspart (authorized generic) Novolog
INSULINS, SHORT-ACTING		Humulin		Novolin
INSULINS, LONG-ACTING		Semglee (yfgn) Tresiba Toujeo		Basaglar Insulin degludec Insulin glargine (yfgn) insulin glargine, hum.rec.anlog (authorized generic) Lantus Levemir Rezvoglar



Preferred Drug List (PDL)

EFFECTIVE DATE JANUARY 1, 2025. THIS LIST IS SUBJECT TO CHANGE

PDL DRUG CATEGORY	GENERIC	PREFERRED BRAND	NON-PREFERRED BRAND	EXCLUDED
INSULIN (LONG-ACTING) AND GLP-1 AGONIST COMBINATIONS		Soliqua Xultophy		
DIABETIC SUPPLIES		Abbott & Lifescan diabetic supplies (Precision, FreeStyle, FreeStyle Neo, OneTouch Ultra, OneTouch Verio) BD insulin syringes BD pen needles		All non-Abbott & non-Lifescan manufacturers of diabetic test strips and meters All non-BD insulin syringes All non-BD pen needles
ENDOCRINE				
ANDROGENS	methyltestosterone testosterone cypionate testosterone enanthate testosterone gel testosterone solution		Androderm patch Kyzatrex Methitest Striant Tlando Xyosted	Natesto Jatenzo
ESTROGENS/ESTROGEN MODIFIERS	estradiol gel estradiol patch estradiol/norethindrone estropipate medroxyprogesterone norethindrone ac-eth progesterone, micronized	Bijuva Combipatch Crinone Duavee Premarin Premphase Prempro	Cenestin Elestrin Enjuvia Imvexxy Prefest	Climara Pro Estring Estrogel Femring Intrarosa Menest Osphena
FERTILITY AGENTS (IF COVERED)	cetorelix ganirelix	Crinone Endometrin Gonal-F Menopur Novarel Ovidrel	Chorionic gonadotropin Follistim AQ Pregnyl	
ELECTROLYTE REGULATION		Lokelma	Veltassa	
OSTEOPOROSIS AGENTS	alendronate calcitonin ibandronate raloxifene risedronate risedronate DR teriparatide	Tymlos		Binosto
WEIGHT REDUCTION (IF COVERED)	diethylpropion orlistat phentermine phendimetrazine topiramate	Saxenda Wegovy Zepbound		Belviq Belviq XR Contrave Plenity Qsymia
GASTROINTESTINAL				
IRRITABLE BOWEL & CONSTIPATION	lubiprostone	Linzess Movantik Trulance Symproic		Ibsrela Motegrity Zelnorm
INFLAMMATORY BOWEL DISEASE AGENTS	balsalazide disodium mesalamine 1.2G	Pentasa 250mg		mesalamine DR 400mg Dipentum



Preferred Drug List (PDL)

EFFECTIVE DATE JANUARY 1, 2025. THIS LIST IS SUBJECT TO CHANGE

PDL DRUG CATEGORY	GENERIC	PREFERRED BRAND	NON-PREFERRED BRAND	EXCLUDED BRAND
	mesalamine DR 800mg mesalamine ER sulfasalazine			
PANCREATIC ENZYMES		Creon Zenpep		Pancreaze Pertzye
GENITOURINARY				
DRUGS TO TREAT IMPOTENCY	sildenafil tadalafil			Stendra vardenafil
INFLAMMATORY DISEASE				
AUTOIMMUNE AGENTS	methotrexate	Otrexup	Xatmep	Rasuvo
PAIN MANAGEMENT				
HEADACHE/ MIGRAINE TREATMENT	almotriptan eletriptan frovatriptan naratriptan rizatriptan sumatriptan zolmitriptan	Aimovig Ajovy Emgality Nurtec ODT Qulipta Reyvow Ubrelvy	Trudhesa Zavzpret	Onzetra Xsail Tosymra Treximet Zembrace Symtouch Zomig Nasal
RESPIRATORY				
BETA-AGONISTS, SHORT-ACTING (SABA)	albuterol HFA levalbuterol HFA			ProAir Digihaler ProAir RespiClick
INHALED CORTICOSTEROIDS (ICS)	fluticasone propionate	Arnuity Ellipta		Aerospan Alvesco Armonair RespiClick Armonair DigiClick Asmanex Pulmicort Flexhaler Qvar Redihaler
INHALED CORTICOSTEROID/LON G-ACTING BETA AGONIST (ICS/LABA) COMBINATIONS	fluticasone/salmeterol budesonide/formoterol	Advair HFA Breo Ellipta		Airduo (brand and authorized generic) Airduo RespiClick Airduo Digihaler Dulera fluticasone furoate- vilanterol (authorized generic) fluticasone-salmeterol (HFA)
INHALED LONG-ACTING BETA AGONIST (LABA)		Perforomist Serevent Diskus Striverdi Respimat	Arcapta Brovana Foradil	
INHALED LONG-ACTING MUSCARINIC ANTAGONISTS (LAMA)		Spiriva Respimat Spiriva Handihaler	Lonhala Magnair	Incruse Ellipta Seebri Neohaler tiotropium bromide Tudorza Pressair Yupelri
INHALED LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA AGONIST (LAMA/LABA) COMBINATIONS		Anoro Ellipta Stiolto Respimat		Duaklir Pressair Utibron Neohaler Bevespi Aerosphere



Preferred Drug List (PDL)

EFFECTIVE DATE JANUARY 1, 2025. THIS LIST IS SUBJECT TO CHANGE

PDL DRUG CATEGORY	GENERIC	PREFERRED BRAND	NON-PREFERRED BRAND	EXCLUDED
INHALED CORTICOSTEROID, LONG-ACTING MUSCARINIC ANTAGONIST, AND LONG-ACTING BETA AGONIST (ICS/LAMA/LABA) COMBINATIONS		Trelegy Ellipta Breztri Aerosphere		
ANTI-LEUKOTRIENES	montelukast zafirlukast			Zyflo Zyflo CR
SPECIALTY				
ANEMIA AGENTS		Retacrit	Mircera	Aranesp Epogen Procrit
ASTHMA BIOLOGICS		Dupixent Fasenra Nucala Xolair Tezspire	Cinqair	
AUTOIMMUNE AGENTS		adalimumab-ADAZ Enbrel Humira Otezla Rinvoq Simlandi Skyrizi Sotyktu Stelara Taltz Tremfya Xeljanz Xeljanz XR	Bimzelx Cimzia Inflectra Kineret Kevzara Olumiant Orencia infliximab Renflexis Simponi 100 mg Simponi 50 mg Simponi Aria Tyenne	Abrilada Actemra Adalimumab-ryvk Amjevita Cosentyx Cyltezo Hadlima Hulio Hyrimoz Idacio Ilumya OmvoH Siliq Tofidence Velsipity Yuflyma Yusimry Zymfentra
GROWTH HORMONES		Norditropin Genotropin Skytrofa Sogroya	Serostim Omnitrope Zorbtive	Humatrope Ngenla Nutropin AQ NuSpin Saizen Zomacton
HEMATOLOGICAL DISORDERS- LEUKOCYTE (WBC) STIMULANTS		Nivestym Ziextenzo	Leukine Udenyca Onbody	Fulphila Flynetra Granix Neulasta Neulasta Onpro Neupogen Nyvepria Relueko Rolvedon Stimufend Udenyca Zarxio



Preferred Drug List (PDL)

EFFECTIVE DATE JANUARY 1, 2025. THIS LIST IS SUBJECT TO CHANGE

PDL DRUG CATEGORY	GENERIC	PREFERRED BRAND	NON-PREFERRED BRAND	EXCLUDED
HEPATITIS C AGENTS		Epclusa Harvoni Vosevi	Mavyret Sovaldi	Zepatier ledipasvir-sofosbuvir sofosbuvir-velpatasvir
MULTIPLE SCLEROSIS AGENTS	Glatopa Glatiramer dalfampridine dimethyl fumarate fingolimod 0.5mg teriflunomide	Avonex Betaseron Copaxone 40mg/mL Kesimpta Pen Mavenclad Mayzent Plegridy Rebif Rebif Rebidose Vumerity	Copaxone 20mg/mL Gilenya 0.25mg Zeposia	Bafiertam Extavia Ponvory Tascenso ODT Tecfidera
ONCOLOGY AGENTS – HORMONE RECEPTOR- POSITIVE BREAST CANCER		Kisqali Kisqali/Femara Co-pack Verzenio	Ibrance	